Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXCEED ET
NCT05482971Phase 2Active, not recruiting
- Sponsor
- PharmaEssentia
- Start
- Sep 2022
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ropeginterferon alfa-2b in essential thrombocythemia (ET), sponsored by PharmaEssentia. Primary endpoint: Durable Response at 52 weeks. Started Sep 2022; status: active, not recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT05482971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482971.